Is pheochromocytoma a secondary cause of hypertension?

Is Pheochromocytoma a Secondary Cause of Hypertension?

Yes, pheochromocytoma is definitively a secondary cause of hypertension and represents one of the most important curable forms of endocrine hypertension. 1

Epidemiology and Clinical Significance

Pheochromocytoma accounts for 0.1–0.6% of all hypertensive patients in general outpatient clinics, making it a rare but critical diagnosis to consider 2. Among patients with resistant hypertension specifically, the prevalence is higher, and nearly 5% of patients with incidentally discovered adrenal masses prove to have a pheochromocytoma 2.

The clinical importance of recognizing pheochromocytoma as a secondary cause cannot be overstated:

• Autopsy series reveal that catecholamine-producing tumors contributed to 55% of deaths and were clinically unsuspected in 75% of cases, underscoring the frequency of missed diagnoses 3
• The mean interval from symptom onset to definitive diagnosis is approximately 3 years, highlighting the diagnostic delay that commonly occurs 3
• Pheochromocytoma represents a potentially curable form of secondary hypertension through surgical resection 1, 4
• If undetected, pheochromocytomas confer a high risk for morbidity and mortality, especially during surgical procedures and pregnancy 5

Classification as Secondary Hypertension

The Canadian Hypertension Education Program explicitly categorizes pheochromocytoma under "Treatment of secondary hypertension due to endocrine causes," alongside hyperaldosteronism 1. This formal classification in major hypertension guidelines confirms its status as a secondary—rather than primary—cause of elevated blood pressure.

Pathophysiology of Hypertension

Pheochromocytomas cause hypertension through excess catecholamine release (epinephrine, norepinephrine, and sometimes dopamine) from chromaffin cell tumors 2. The hypertension manifests in two distinct patterns:

• Approximately 50% of patients have sustained hypertension between catecholamine surges 3
• The other 50% exhibit paroxysmal hypertensive spikes with normal or near-normal blood pressure between episodes 3
• More than 90% of individuals with pheochromocytoma present with severe hypertension 3

Higher norepinephrine secretion is directly associated with greater blood-pressure variability and more pronounced sustained hypertension 3.

Clinical Presentation

The classic triad of episodic headache, palpitations, and sweating has approximately 90% diagnostic specificity for pheochromocytoma in adults presenting with resistant hypertension 3. Additional features include:

• Resistant hypertension (e.g., systolic ≥190 mmHg despite high-dose β-blocker and ACE-inhibitor therapy) 3
• Tachycardia as a cardinal sign, frequently accompanied by palpitations 3
• Excessive sweating (diaphoresis) occurs in 60–70% of patients 3
• Facial flushing, intermittent pallor, tremor, unexplained weight loss, and nausea 3
• Approximately 95% of patients experience paroxysmal symptoms 3

Importantly, approximately 15% of patients with pheochromocytoma have no prior history of hypertension, which can make diagnosis challenging 3.

When to Screen for Pheochromocytoma

The Endocrine Society recommends testing in the following clinical settings 2:

• Signs and symptoms of pheochromocytoma, particularly if paroxysmal or provoked by medications
• Adrenal incidentaloma, with or without hypertension
• Hereditary predisposition or syndromic features suggesting hereditary pheochromocytoma
• Previous history of pheochromocytoma

In children with hypertension, the prevalence of pheochromocytoma is approximately 1.7%, making it an important consideration in pediatric secondary hypertension 2.

Diagnostic Approach

Initial biochemical testing should include measurements of plasma free metanephrines or urinary fractionated metanephrines 2. Specifically:

• Plasma free metanephrines offer 99% sensitivity and 89% specificity for pheochromocytoma 3
• 24-hour urinary fractionated metanephrines provide 77–97% sensitivity and 69–98% specificity 3
• Plasma metanephrine concentrations exceeding 3–4× the upper reference limit are highly diagnostic 3

Certain medications (tricyclic antidepressants, decongestants, amphetamines, reserpine, phenoxybenzamine) can cause false-positive results and should be discontinued before biochemical testing 3.

Common Pitfalls

• Never assume hypertension is "essential" in young adults with severe hypertension; always consider secondary causes including pheochromocytoma 3
• Do not rule out pheochromocytoma solely because blood pressure is normal; catecholamine excess can provoke symptoms without sustained hypertension 3
• Avoid adrenal biopsy in suspected cases, as it can precipitate a hypertensive crisis 6
• All patients with incidental adrenal tumors should be biochemically screened for pheochromocytoma before resection or needle biopsy to avoid precipitation of a lethal hypertensive crisis 5

Management Implications

Once diagnosed, treatment of benign pheochromocytoma should be surgical resection 1. Critical pre-operative management includes:

• Alpha-blockers (prazosin, doxazosin, phenoxybenzamine) should be used as first-line agents for 10–14 days before surgery 1, 7
• Beta-blockers must not be started before adequate alpha-blockade to avoid unopposed alpha-stimulation and hypertensive crisis 1, 7
• Laparoscopic surgery should be considered before open surgery for resection, except for very large tumors 1

Positive biochemical results warrant referral to a specialized hypertension center for confirmatory imaging and multidisciplinary management 3.